Popular this month
Search News Archives
Call for Posters: PREP 2015 July 26-29, 2015 in Philadelphia, PA, USA
Randox provide state of the art solutions for workplace drug testing
The multiplexing Biochip Array Technology allows clinicians to detect up to 97 drug metabolites from one sample simultaneously. The ability to carry out simultaneous tests on a biochip has lead to significant time and labour savings in WDT, whereas traditionally only one drug could be detected at a time. The Randox Biochip portfolio incorporates a range of illicit and prescription drugs which can be mis-used, putting employees at risk while they are at work. High risk industries which commonly employ WDT include construction, manufacturing, transport, education and security.
Last year, The National Institute on Drug Abuse (NIDA) published a report indicating that drug abuse worldwide was at its highest level in nearly a decade. Findings revealed that the most commonly abused drug is Marijuana; however non-medical use of prescription drugs is also increasing. In 2010, Randox Global Toxicology Manager Richard Bell revealed that they had experienced significant growth in the demand for their range of workplace drug testing products;
"Workplace drug testing is becoming a necessity prior to employment, both for the safety of employees and members of the public who they may come in contact with. We cannot ignore the fact that drug mis-use is on the rise. Randox are continuously developing our drug screening test menu to accommodate companies carrying out a workplace drug testing program."
As well as diagnostic solutions for onsite testing and laboratory testing, Randox also provide an employee screening service to companies.
Headquartered in the United Kingdom, Randox Laboratories Ltd. is a market leader within the in vitro diagnostics industry, manufacturing high quality diagnostic products for laboratories worldwide. Our extensive product portfolio offers complete solutions within the fields of clinical and forensic toxicology, clinical chemistry, cardiology, veterinary, drug residues, life sciences, oncology, molecular diagnostics and internal and external quality control. A continuous strategy of innovation has allowed Randox to revolutionise technology for the clinical toxicology market. Significant re-investment in Research and Development has seen the novel Biochip Array Technology adapt and evolve, with four analysers available for various settings.
Substance Abuse and Mental Health Services Administration, 2010. Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of National Findings
Exhibitions & Events